Literature DB >> 23425501

Early surgery for native valve infective endocarditis.

Khursheed Haider, Michael R Pinsky.   

Abstract

BACKGROUND: The timing and indications for surgical intervention to prevent systemic embolism in infective endocarditis (IE) remain controversial. This trial compares clinical outcomes of early surgery and conventional treatment in patients with IE. METHODS
RESULTS: Thirty-seven patients were assigned to the early-surgery group (<48 hours), whereas 39 were assigned to conventional therapy. Of the 39 randomly assigned to conventional therapy, 27 patients (77%) underwent surgery during the initial hospitalization and three during follow-up. One patient (3%) in the early-surgery group and nine (23%) in the conventional-treatment group reached the primary endpoint (hazard ratio (HR) 0.10, 95% confidence interval (CI) 0.01 to 0.82; P = 0.03). There was no significant difference in all-cause mortality at 6 months in the early-surgery and conventional-treatment groups (3% and 5%, respectively; HR 0.51, 95% CI 0.05 to 5.66; P = 0.59). The rates of the composite endpoint of death from any cause, embolic events, or recurrence of IE at 6 months were 3% in the early-surgery group and 28% in the conventional-treatment group (HR 0.08, 95% CI 0.01 to 0.65; P = 0.02).
CONCLUSIONS: Early surgery in patients with IE and large vegetations significantly reduced the composite endpoint of death from any cause and embolic events by effectively decreasing the risk of systemic embolism.

Entities:  

Mesh:

Year:  2013        PMID: 23425501      PMCID: PMC4057157          DOI: 10.1186/cc12497

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


Commentary

Even with recent advancement in modern health science, infective endocarditis (IE) remains a disease associated with significant morbidity and mortality [1]. Its incidence increased from 5 to 7.9 cases per 100,000 person-years in Minnesota from 1970 to 2007 [2]. The role of surgical intervention is increasing, and better outcomes are being realized [3]. Current guidelines of the American Heart Association (AHA) favor early surgical intervention in heart failure, but indications for surgery to prevent systemic embolization are not clear [4,5]. Although the European Society of Cardiology has strongly recommended urgent surgery (within a few days) for a vegetation size of greater than 10 mm in an effort to prevent systemic embolization, evidence to support this aggressive approach is based mainly on observational studies [6,7]. Several randomized control trials (RCTs) have been conducted to determine choice and duration of antibiotics for IE, but no RCT regarding timing and indication of surgery is available. Early surgery may be beneficial since most emboli occur during the first week following the start of therapy, and the majority of these are cerebral emboli, which lead to poor outcomes [8]. This study was designed to address the role of timing of surgery in the prevention of systemic embolization in patients without heart failure but with large vegetations (>10 mm). All 39 patients in early intervention group underwent surgery, whereas only 30 (77%) of the 39 patients in the conservative group had surgery, presumably because it was felt to be indicated. In the conservative group, eight (21%) had indications for urgent surgery (mean time of 6.5 days after random assignment), and 22 (56%) had elective surgery after 2 weeks because of left ventricular dysfunction. The early-surgery group had no embolic events, whereas the conservative group had eight (21%) cases of documented systemic embolization (0% versus 21%, P = 0.005). All embolic events occurred during the first 6 weeks (primary endpoint). In both groups, there was no significant difference in mortality at 6 weeks (3% versus 5%, P = 1.00) or 6 months (secondary endpoint). The results of this study suggest that early surgical intervention significantly reduces the incidence of major embolic events without altering other short- and long-term endpoints. This study is important because it is the first randomized clinical trial to address a subgroup of patients with large vegetations without heart failure. The significance of this study lies in the low pre-existing morbidity of the patients and the potential for real improvement in quality of life if significant embolization is avoided. Given the findings of the study, the AHA may modify its recommendations on the treatment of patients with IE and large vegetations. Interestingly, the overall mortality was lower in this study than the other observational studies of IE (5% versus 27%) [9]. This lower mortality may be related to strict inclusion criteria and excluding patients with complicated IE. Another possibility for the observed lower mortality in all subjects may be related to low incidence of Staphylococcal infection, an important risk factor for death in IE [10,11]. This study does not include patients with prosthetic valve, major stroke, and right-sided endocarditis, and this makes its recommendations limited in scope. Furthermore, though it is an RCT, it is not blinded, and this can cause ascertainment bias. Thus, it is difficult to generalize these results to all patients presenting with IE and large vegetations. Although this is a small RCT, it signals a new era in conducting RCTs to determine optimal surgical approaches for patients with IE. Interestingly, in 2008, a larger RCT testing optimal timing of surgery for IE was also initiated (NCT00624091) [12]. That study is ongoing and is testing the role of timing of surgery for other indications, such as prosthetic heart valves and complicated IE. It will be interesting to see whether early surgery remains superior for preventing complications in this larger diverse group of patients.

Recommendation

Early surgical repair of patients with left-sided IE and large vegetations results in a markedly reduced incidence of long-term embolic complications without altering mortality as compared with using antibiotics alone and elective surgical repair.

Abbreviations

AHA: American Heart Association; IE, infective endocarditis; RCT, randomized control trial.

Competing interests

The authors declare that they have no competing interests.

Note

University of Pittsburgh Department of Critical Care Medicine: Evidence-Based Medicine Journal Club, edited by Sachin Yende
  12 in total

1.  Epidemiological trends of infective endocarditis: a population-based study in Olmsted County, Minnesota.

Authors:  Daniel D Correa de Sa; Imad M Tleyjeh; Nandan S Anavekar; Jason C Schultz; Justin M Thomas; Brian D Lahr; Alok Bachuwar; Michal Pazdernik; James M Steckelberg; Walter R Wilson; Larry M Baddour
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

2.  The impact of valve surgery on 6-month mortality in left-sided infective endocarditis.

Authors:  Imad M Tleyjeh; Hassan M K Ghomrawi; James M Steckelberg; Tanya L Hoskin; Zaur Mirzoyev; Nandan S Anavekar; Felicity Enders; Sherif Moustafa; Farouk Mookadam; W Charles Huskins; Walter R Wilson; Larry M Baddour
Journal:  Circulation       Date:  2007-03-19       Impact factor: 29.690

3.  Time-related distribution, risk factors and prognostic influence of embolism in patients with left-sided infective endocarditis.

Authors:  José Fabri; Victor Sarli Issa; Pablo M A Pomerantzeff; Max Grinberg; Antonio Carlos Pereira Barretto; Alfredo José Mansur
Journal:  Int J Cardiol       Date:  2005-10-06       Impact factor: 4.164

Review 4.  ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons.

Authors:  Robert O Bonow; Blase A Carabello; Chatterjee Kanu; Antonio C de Leon; David P Faxon; Michael D Freed; William H Gaasch; Bruce Whitney Lytle; Rick A Nishimura; Patrick T O'Gara; Robert A O'Rourke; Catherine M Otto; Pravin M Shah; Jack S Shanewise; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; David P Faxon; Valentin Fuster; Jonathan L Halperin; Loren F Hiratzka; Sharon A Hunt; Bruce W Lytle; Rick Nishimura; Richard L Page; Barbara Riegel
Journal:  Circulation       Date:  2006-08-01       Impact factor: 29.690

5.  Changing patient characteristics and the effect on mortality in endocarditis.

Authors:  Christopher H Cabell; James G Jollis; Gail E Peterson; G Ralph Corey; Deverick J Anderson; Daniel J Sexton; Christopher W Woods; L Barth Reller; Thomas Ryan; Vance G Fowler
Journal:  Arch Intern Med       Date:  2002-01-14

6.  Staphylococcus aureus endocarditis: a consequence of medical progress.

Authors:  Vance G Fowler; Jose M Miro; Bruno Hoen; Christopher H Cabell; Elias Abrutyn; Ethan Rubinstein; G Ralph Corey; Denis Spelman; Suzanne F Bradley; Bruno Barsic; Paul A Pappas; Kevin J Anstrom; Dannah Wray; Claudio Q Fortes; Ignasi Anguera; Eugene Athan; Philip Jones; Jan T M van der Meer; Tom S J Elliott; Donald P Levine; Arnold S Bayer
Journal:  JAMA       Date:  2005-06-22       Impact factor: 56.272

7.  Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study.

Authors:  Franck Thuny; Giovanni Di Salvo; Giovanni Disalvo; Olivier Belliard; Jean-François Avierinos; Valeria Pergola; Valerie Rosenberg; Jean-Paul Casalta; Joanny Gouvernet; Geneviève Derumeaux; Diana Iarussi; Pierre Ambrosi; Raffaele Calabró; Raffaello Calabro; Alberto Riberi; Frédéric Collart; Dominique Metras; Hubert Lepidi; Didier Raoult; Jean-Robert Harle; Pierre-Jean Weiller; Ariel Cohen; Gilbert Habib
Journal:  Circulation       Date:  2005-06-27       Impact factor: 29.690

8.  Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer.

Authors:  Gilbert Habib; Bruno Hoen; Pilar Tornos; Franck Thuny; Bernard Prendergast; Isidre Vilacosta; Philippe Moreillon; Manuel de Jesus Antunes; Ulf Thilen; John Lekakis; Maria Lengyel; Ludwig Müller; Christoph K Naber; Petros Nihoyannopoulos; Anton Moritz; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

9.  Increasing incidence and mortality of infective endocarditis: a population-based study through a record-linkage system.

Authors:  Ugo Fedeli; Elena Schievano; Dora Buonfrate; Giampietro Pellizzer; Paolo Spolaore
Journal:  BMC Infect Dis       Date:  2011-02-23       Impact factor: 3.090

10.  Serum oestrogen levels in postmenopausal women: comparison of American whites and Japanese in Japan.

Authors:  H Shimizu; R K Ross; L Bernstein; M C Pike; B E Henderson
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

View more
  2 in total

1.  Vertebral Osteomyelitis and Infective Endocarditis Co-Infection.

Authors:  Tadatsugu Morimoto; Hirohito Hirata; Koji Otani; Eiichiro Nakamura; Naohisa Miyakoshi; Yoshinori Terashima; Kanichiro Wada; Takaomi Kobayashi; Masatoshi Murayama; Masatsugu Tsukamoto; Masaaki Mawatari
Journal:  J Clin Med       Date:  2022-04-18       Impact factor: 4.964

2.  Spontaneous spondylodiscitis and endocarditis: interdisciplinary experience from a tertiary institutional case series and proposal of a treatment algorithm.

Authors:  Lennart Viezens; Marc Dreimann; André Strahl; Annika Heuer; Leon-Gordian Koepke; Benjamin Bay; Christoph Waldeyer; Martin Stangenberg
Journal:  Neurosurg Rev       Date:  2021-09-11       Impact factor: 3.042

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.